title: Screening of venlafaxine hydrochloride for transdermal delivery: passive diffusion and iontophoresis.
abstract: The objective of the study was to investigate in vitro transdermal delivery of venlafaxine hydrochloride across the pigskin by passive diffusion and iontophoresis. For passive diffusion, experiments were carried out in Franz diffusion cell whereas for iontophoretic permeation, the diffusion cell was modified to contain both the donor and return electrode on the same side of skin. Anodal iontophoresis was carried out using a current density of 0.5 mA/cm(2). Donor concentrations used were 585.5 mg/ml (saturated solution) and 100 mg/ml. Experiments initially performed to determine the transport efficiency of venlafaxine ions showed promising results. Iontophoresis increased the permeation rate at both concentration levels over their passive counterparts (P < 0.01), but surprisingly higher steady-state flux was obtained from lower donor drug load (P < 0.01). The favorable pH of the unsaturated solutions is suggested to be the cause for this effect. Mild synergistic effect was observed when iontophoresis was carried out incorporating peppermint oil in the donor but the same was not found in passive diffusion. Highest steady-state flux obtained in the experiment was 3.279 mumol/cm(2)/h when peppermint oil (0.1%) was included in the donor. As the maintenance requirement of venlafaxine hydrochloride is approximately 9.956 mumol/h, the results suggested that the drug is a promising candidate for iontophoretic delivery.
authors.affiliation: Research associate, Formulation and Development, Cadila Pharmaceuticals Ltd., Ahmedabad, India.
authors.forename: Gursharanjit
authors.initials: G
authors.lastname: Singh
authors.forename: Bijaya
authors.initials: B
authors.lastname: Ghosh
authors.forename: Dave
authors.initials: D
authors.lastname: Kaushalkumar
authors.forename: Vanita
authors.initials: V
authors.lastname: Somsekhar
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D003511:Cyclohexanols / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004058:Diffusion / Q000187:drug effects; D004353:Drug Evaluation, Preclinical / Q000379:methods; D007478:Iontophoresis / Q000379:methods*; D012869:Skin Absorption / Q000187:drug effects* / Q000502:physiology; D012995:Solubility / Q000187:drug effects; D013552:Swine; D000069470:Venlafaxine Hydrochloride
chemical_list: D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride